Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IvAzCol: Ivermectin, Azithromycin, and Cholecalciferol for COVID-19
NCT04399746Completed
- Sponsor
- ISSSTE
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label trial of ivermectin, azithromycin and vitamin d in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ISSSTE. Primary endpoint: Viral clearance at 14 days. Started Mar 2020; status: completed.
02
Drugs
ivermectinazithromycinvitamin d
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04399746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399746.